NAC for Attenuation of COVID-19 Symptomatology
Launched by CAMBRIDGE HEALTH ALLIANCE · Oct 5, 2021
Trial Information
Current as of July 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "NAC for Attenuation of COVID-19 Symptomatology," is looking to see if a medication called NAC (N-acetylcysteine) can help reduce the severity and duration of symptoms in people who have COVID-19. The study will involve adults aged 65 to 74 who have tested positive for COVID-19 within the last 7 days. However, pregnant individuals or those who are already in the hospital due to COVID-19 will not be able to participate.
If you or a family member qualify and decide to join the study, you can expect to take the oral NAC medication and be monitored for any changes in symptoms. The goal is to see if NAC can make a difference in how long and how severely COVID-19 affects patients. This trial is not currently recruiting participants, but it aims to provide valuable information about potential treatments for COVID-19 in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • positive COVID test \<= 7 days of enrollment
- Exclusion Criteria:
- • pregnant
- • already hospitalized due to COVID
About Cambridge Health Alliance
Cambridge Health Alliance (CHA) is a prominent healthcare system in Massachusetts, dedicated to providing high-quality, community-centered health services. As a clinical trial sponsor, CHA leverages its robust research infrastructure and commitment to innovation to advance medical knowledge and improve patient outcomes. With a focus on diverse populations, CHA conducts clinical trials across various therapeutic areas, ensuring that research is inclusive and reflective of the community it serves. The organization is committed to ethical standards and regulatory compliance, fostering collaboration among healthcare professionals, researchers, and participants to drive advancements in clinical care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Everett, Massachusetts, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials